Crothall Healthcare Celebrates Hospital Partners Honored in 2026 Practice Greenhealth Awards

We are incredibly proud to celebrate our hospital partners who have been recognized in the 2026 Practice Greenhealth Environmental Excellence Awards. Several of our partners were honored across multiple award categories, including the prestigious Top 25 Environmental Excellence Award list, the organization’s highest honor for hospitals.  At Compass Healthcare, sustainability is a core part of how we support our partners and our communities. These awards are more…

Read More

Belgian Sleep Medicine Company Begins Providing Care In The US Through New Acquisition

Belgian sleep diagnostics company Sunrise announced the acquisition of Dreem Health, a California-based sleep clinic. This has allowed Sunrise to provide its telehealth-based sleep care in California, Iowa, Maryland and Washington, with plans to be available nationwide next year. The post Belgian Sleep Medicine Company Begins Providing Care In The US Through New Acquisition appeared…

Read More

Crothall’s Carolyn Mixon Celebrates 60 Years in Healthcare

One of Crothall’s longest-running associates recently celebrated her 60th work anniversary in the healthcare industry.  Carolyn Mixon, Environmental Services operations manager at Walker Baptist Medical Center in Jasper, Alabama, began working as a housekeeper in 1965. She started her career at the former Peoples Hospital and moved to Walker Baptist when it opened in 1980.  To celebrate this milestone, her friends and co-workers presented the 80-year-old with a certificate and a plaque, and treated her to dinner at a…

Read More

Workplace Violence Prevention in 2025

Workplace violence prevention is an ongoing and organic process. Federal and state regulations change frequently, so employers may consider regularly reviewing and updating their prevention plans and training programs on a scheduled timeline. The post Workplace Violence Prevention in 2025 appeared first on MedCity News.

Read More

Startup Glycomine Lands $115M for Clinical Trial in Ultra-Rare Disease With No Approved Drugs

Glycomine’s lead program is an experimental treatment for PMM2-CDG, an ultra-rare enzyme deficiency often misdiagnosed as cerebral palsy. With encouraging results from an open-label Phase 2 study, the biotech startup is now preparing for a placebo-controlled test that could potentially support a regulatory submission. The post Startup Glycomine Lands $115M for Clinical Trial in Ultra-Rare…

Read More

Links

Impact of robots on workers comp.What drives low income inequality in Nordic countries?Wean patients off GLP-1s?Ebola outbreak.Will Most Favored Nation backfire?

Read More